-
-
-
-
-
-
-
ProMIS shares new data on plasma biomarker for alzheimer's trials
-
-
-
-
-
-
-
ProMIS Neurosciences (PMN) Appoints Dr. Slanix Paul Alex to Board
-
-
-
-
-
-
-
ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer’s Association International Conference
-
-
-
-
-
-
-
ProMIS Neurosciences receives FDA fast track status for Alzheimer's drug
-
-
-
-
-
-
-
ProMIS Neurosciences (PMN) Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases
-
-
-
-
-
-
-
ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer’s Disease
-
-
-
-
-
-
-
ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

